

Case 7

Bone marrow and blood involvement in a dog with mammary gland carcinoma

Laetitia Jaillardon¹, Corinne Fournel-Fleury²

¹Biology and Pathology Department, LDHvet-ONIRIS, Nantes, France

²Hematology-Cytology-Immunology Laboratory, Pathology Department, National Veterinary School, Lyon, France

Laetitia JAILLARDON <laetitia.jaillardon@oniris-nantes.fr>

Cytological description and differential morphologic diagnoses of large atypical round cells in blood:

The large atypical round cells in blood were isolated or in little sheets, with a moderate nuclear to cytoplasmic ratio, an ovoid nucleus with finely stippled chromatin pattern and numerous prominent nucleoli. Their cytoplasm was highly basophilic, with borders characterized by villous projections (Figures 1 and 2). The differential diagnosis of these cells includes megakaryocytic lineage cells, histiocytic/dendritic cells or non-hematopoietic cells.

Further complementary tests:

A cytology sample obtained from the mammary mass was air dried and stained with May-Grünwald Giemsa stain (Figure 3). Cytologic evaluation of fine needle aspirate specimens revealed a highly cellular and inflammatory sample, focally necrotic, with a population of large atypical round cells organized in thick tridimensional epithelial clumps. The nucleocytoplasmic ratio was moderate with an ovoid and hyperchromatic nucleus containing numerous prominent nucleoli and a highly basophilic cytoplasm. There was marked anisocaryosis and anisocytosis (Figure 3). Those cells were cytomorphologically similar to those found in the blood smear (Figure 5).

Bone marrow cytology revealed a marked hemorrhagic background and a moderate cellular specimen. A few isolated large atypical round cells (or clumps), with the same cytomorphological characteristics as in the mammary specimen, were found (Figures 4 and 5).

Immunocytochemistry on buffy coat, bone marrow and mammary specimens revealed the same positivity of the large atypical round cells described above for intracellular cytokeratins, AE1/AE3 and KL-1. (Figure 6)

Diagnosis and outcome:

This is consistent with a diagnosis of aggressive mammary carcinoma with secondary disseminated intravascular coagulation and disseminated tumour cells in bone marrow and circulating tumour cells in blood.

Due to the deterioration of the dog's clinical and biological status, euthanasia was decided. In accordance with the owner's decision, no necropsy was performed.

Discussion:

To our knowledge, this is the first documented case of disseminated and circulating tumour cells of mammary gland carcinoma in a dog. Circulating neoplastic cells have been reported in dogs in a case of extragenital transmissible tumor¹, disseminated histiocytic sarcoma² and dendritic cell leukaemia³. In the present case, evaluation of the buffy coat smear seemed to be a useful tool for identifying the circulating tumor cells and for performing immunocytochemistry. In humans, the detection and biological relevance of disseminated and circulating tumour cells in cancer patients, particularly those with breast cancer, have been largely investigated in order to detect metastatic relapse caused by minimal residual disease (presence of tumour cells that are not detectable by the current routine diagnostic procedures) after treatment. Such cells seem to represent a poor prognostic factor for patient outcome and response to therapy^{4,5,6}.

Disseminated intravascular coagulation (DIC) has been proved to be involved in solid tumours in humans and dogs, including mammary gland carcinoma^{7,8}. The exact mechanism by which DIC occurs in solid tumour is not fully understood. It has been demonstrated in humans and animals that solid tumour cells have the ability to express different procoagulant molecules (including Tissue Factor and cancer procoagulant⁹) and to express fibrinolytic proteins. Furthermore, the role of pro-inflammatory cytokines (IL6 and TNF α for example) has been demonstrated to also contribute to the occurrence of DIC in cancer patients¹⁰. In addition, the role of the balance in the expression profiles of COX-derived prostanoids, prostacyclin (PGI₂) and thromboxane (TXA₂) may be of critical importance in the development and progression of cancer, in part by promoting an increase in thrombosis¹¹. In dogs, the frequency and intensity of coagulation parameter abnormalities appear to be correlated with tumour progression as well as with tumour stage and metastasis for aPTT, fibrinogen, fibrin monomers and antithrombin III. However, clinical evidence of an increased bleeding tendency has not been frequently encountered⁷. DIC has been reported to occur in 12.2% of the dogs with malignant solid tumors including ones with mammary gland carcinoma¹². A recent study of the evaluation of thromboelastography in dogs with various neoplasms, demonstrated a significant incidence of the hypercoagulable state in canine malignant cancer. Interestingly in this study, only dogs with metastatic disease were observed to have an overall hypocoagulable state¹³.

The present case demonstrates that haematogenous metastasis exists in canine mammary carcinoma by providing evidence of tumour cells escape from the primary tumour mass into the bloodstream and bone marrow. The disseminated intravascular coagulation could be associated with the haematogenous metastasis since the development and progression of cancer depends partly on the cancer-related thrombosis. The buffy coat smear could be a relevant complementary test to detect circulating tumour cells when DIC of unknown origin occurs in dogs.

References

1. Albanese F, Salerni FL, Giordano S, Marconato L. Extragenital transmissible venereal tumour associated with circulating neoplastic cells in an immunologically compromised dog. *Vet Comp Oncol.* 2006;4:57-62
2. Rossi S, Gelain ME, Comazzi S. Disseminated histiocytic sarcoma with peripheral blood involvement in a Bernese Mountain dog. *Vet Clin Pathol.* 2009;38:126-130
3. Allison RW, Brunker JD, Breshears MA et al. Dendritic cell leukemia in a Golden Retriever. *Vet Pathol.* 2008;37:190-197
4. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. *Nat Rev Cancer.* 2008;8:329-340
5. Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. *Int J Cancer.* 2008;123:1991-2006
6. Riethdorf S, Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. *Pathobiology.* 2008;75:140-148
7. Stockhaus C, Kohn B, Rudolph R, Brunnberg L, Giger U. Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. *J Small Anim Pract.* 1999;40:326-331
8. Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated Intravascular Coagulation in solid tumors: clinical and pathologic study. *Thromb Haemost.* 2001;86:828-833
9. DelGiudice LA, White GA. The role of tissue factor and tissue factor pathway inhibitor in health and disease states. *J Vet Emerg Crit Care.* 2009;19:23-29
10. Levi M. Disseminated intravascular coagulation in cancer patients. *Best Pract Res Clin Haematol.* 2009;22:129-136
11. Cathcart MC, Reynolds JV, O'Byrne KJ, Pidgeon GP. The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. *Biochim Biophys Acta.* 2010;1805:153-166
12. Maruyama H, Miura T, Koie H et al. The incidence of disseminated intravascular coagulation in dogs with malignant tumor. *J Vet Med Sci.* 2004;66:573-575
13. Kristensen AT, Wiinberg B, Jessen LR, Andreasen E, Jensen AL. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. *J Vet Intern Med.* 2008;22:140-147




Fig.3: Mammary mass. May Grunwald Giemsa. 400X




Fig.4: Bone marrow. May Grunwald Giemsa. 400X




Fig. 5: Similar cytomorphological characteristics of the cells found in the buffy coat smear (A), the bone marrow (B) and the mammary mass (C). May Grunwald Giemsa.400X




Fig.6: Immunocytochemistry on buffy coat smear. Positivity to intracellular cytokeratins AE1/AE3. 1000X